These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation. Youdim MB; Weinstock M Neurotoxicology; 2004 Jan; 25(1-2):243-50. PubMed ID: 14697899 [TBL] [Abstract][Full Text] [Related]
5. Tyramine and new monoamine oxidase inhibitor drugs. Simpson GM; de Leon J Br J Psychiatry Suppl; 1989 Oct; (6):32-7. PubMed ID: 2695125 [TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacology of MAO inhibitors: safety and future. Yamada M; Yasuhara H Neurotoxicology; 2004 Jan; 25(1-2):215-21. PubMed ID: 14697896 [TBL] [Abstract][Full Text] [Related]
7. The transdermal delivery system of monoamine oxidase inhibitors. VanDenBerg CM J Clin Psychiatry; 2012; 73 Suppl 1():25-30. PubMed ID: 22951239 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of monoamine oxidase inhibitors. Mallinger AG; Smith E Psychopharmacol Bull; 1991; 27(4):493-502. PubMed ID: 1813896 [TBL] [Abstract][Full Text] [Related]
9. Studies of selective and reversible monoamine oxidase inhibitors. Mann JJ; Aarons SF; Frances AJ; Brown RD J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):62-6. PubMed ID: 6429130 [TBL] [Abstract][Full Text] [Related]
10. Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide. Nair NP; Ahmed SK; Kin NM J Psychiatry Neurosci; 1993 Nov; 18(5):214-25. PubMed ID: 7905288 [TBL] [Abstract][Full Text] [Related]
14. [Antidepressive action, pharmacokinetic characteristics and biochemical properties of cimoxatone, a new reversible MAO-A inhibitor]. Poirier MF; Olié JP; Lôo H; Deniker P; Strolin Benedetti M; Rovei V; Lesage A Encephale; 1983; 9(4):331-43. PubMed ID: 6368197 [TBL] [Abstract][Full Text] [Related]
15. [Rational use of antidepressants in general medicine]. Verbanck P; Cnockaert P Rev Med Brux; 1996 Sep; 17(4):224-9. PubMed ID: 8927850 [TBL] [Abstract][Full Text] [Related]
16. [The interactions of antidepressant drugs]. Zapotoczky HG; Simhandl CA Wien Klin Wochenschr; 1995; 107(10):293-300. PubMed ID: 7785275 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy. Löscher W; Lehmann H; Teschendorf HJ; Traut M; Gross G J Pharmacol Exp Ther; 1999 Mar; 288(3):984-92. PubMed ID: 10027835 [TBL] [Abstract][Full Text] [Related]
18. Elucidating the mechanism of action and potential interactions of MAO-B inhibitors. Bainbridge JL; Page RL; Ruscin JM Neurol Clin; 2008 Aug; 26(3 Suppl):S85-96, vi. PubMed ID: 18774444 [TBL] [Abstract][Full Text] [Related]
19. Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. Stahl SM; Felker A CNS Spectr; 2008 Oct; 13(10):855-70. PubMed ID: 18955941 [TBL] [Abstract][Full Text] [Related]
20. The advent of a new generation of monoamine oxidase inhibitor antidepressants: pharmacologic studies with moclobemide and brofaromine. Lavian G; Finberg JP; Youdim MB Clin Neuropharmacol; 1993; 16 Suppl 2():S1-7. PubMed ID: 8313392 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]